HiResolution Bionic Ear System
Advanced Bionics · Decision date Jul 22, 2026
What did the FDA approve?
FDA records P960058/S167 as a supplement to PMA P960058, with the supplement type “Panel Track”. The recorded decision is approval, dated Jul 22, 2026.
FDA approval order statement
Unilateral Hearing Loss The HiResolution Bionic Ear System is indicated for individuals with unilateral hearing loss who meet the following criteria: Asymmetric Hearing Loss (AHL) Individuals with AHL are defined as those with a mild to moderately severe hearing loss in the better ear, i.e., a 4PTA of 31 to 65 dB HL at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz, with a difference of at least 15 dB in the 4PTA between ears. It is recommended that individuals with AHL have at least two (2) weeks experience wearing an appropriately fitted Contralateral Routing of Signal (CROS) system or suitable hearing device prior to cochlear implantation. The ear to be implanted will be as follows: Adults (18 years of age or older): Severe to profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 80 dB HL) A score of = 20% on a Consonant-Nucleus-Consonant (CNC) word test Children (5 years through 17 years of age): Profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 90 dB HL) Insufficient functional access to sound in the ear to be implanted must be determined by aided speech perception test scores of 5% or less on a developmentally appropriate monosyllabic word list when tested in the ear to be implanted alone. Single-Sided Deafness (SSD) Individuals with SSD are defined as those with normal hearing or mild sensorineural hearing loss in the better ear (4PTA of = 30 dB HL at 500, 1000, 2000, and 4000 Hz). It is recommended that individuals with SSD have at least two (2) weeks experience wearing an appropriately fitted Contralateral Routing of Signal (CROS) system or suitable hearing device prior to cochlear implantation. The ear to be implanted will be as follows: Adults (18 years of age or older): Severe to profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 80 dB HL) A score of = 20% on a Consonant-Nucleus-Consonant (CNC) word test Children (5 years through 17 years of age): Profound sensorineural hearing loss (4PTA of 500, 1000, 2000, and 4000 Hz = 90 dB HL) Insufficient functional access to sound in the ear to be implanted must be determined by aided speech perception test scores of 5% or less on a developmentally appropriate monosyllabic word list when tested in the ear to be implanted alone.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Jul 22, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P960058/S167
- Regulatory pathway
- PMA supplement
- Applicant
- Advanced Bionics
- Product code
- MCM
- Decision code
- APPR
- Decision date
- Jul 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, cochlear.
- Applicant
- Advanced Bionics
- Product code
- MCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960058. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960058 · Original PMA
CLARION MULTI-STRATEGY COCHLEAR IMPLANT
P960058/S167 received
Application receipt date recorded by FDA.
P960058/S171 · Related supplement
HiResolution Bionic Ear System
P960058/S172 · Related supplement
HiResolution Bionic Ear System
P960058/S170 · Related supplement
HiResolution Bionic Ear System
P960058/S174 · Related supplement
HiResolution Bionic Ear System Ultra and Ultra 3D Thin PCB
P960058/S173 · Related supplement
HiResolution Bionic Ear System
P960058/S175 · Related supplement
HiResolution Bionic Ear System
P960058/S167 · FDA decision
Panel Track
P960058/S177 · Related supplement
HiResolution Bionic Ear System
P960058/S178 · Related supplement
CLARION MULTI-STRATEGY COCHLEAR IMPLANT
Timeline entries are records held by MedtechLedger for P960058. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960058
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Advanced Bionics | PMA approval | Jun 26, 1997 | FDA | |
HiResolution Bionic Ear SystemP960058/S171 | Advanced Bionics | PMA supplement | Aug 20, 2025 | FDA |
HiResolution Bionic Ear SystemP960058/S172 | Advanced Bionics | PMA supplement | Oct 14, 2025 | FDA |
HiResolution Bionic Ear SystemP960058/S170 | Advanced Bionics | PMA supplement | Jan 23, 2026 | FDA |
| Advanced Bionics | PMA supplement | Apr 9, 2026 | FDA | |
HiResolution Bionic Ear SystemP960058/S173 | Advanced Bionics | PMA supplement | Apr 16, 2026 | FDA |
HiResolution Bionic Ear SystemP960058/S175 | Advanced Bionics | PMA supplement | Apr 16, 2026 | FDA |
HiResolution Bionic Ear SystemP960058/S177 | Advanced Bionics | PMA supplement | Sep 4, 2026 | FDA |
CLARION MULTI-STRATEGY COCHLEAR IMPLANTP960058/S178 | Advanced Bionics | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code MCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MED-EL Cochlear Implant SystemP000025/S136 | Med-El Corp. | PMA supplement | Oct 9, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP840024/S099 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP890027/S067 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 24 Cochlear Implant SystemP970051/S244 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 24 Cochlear Implant SystemP970051/S242 | Cochlear Americas | PMA supplement | Apr 30, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Advanced Bionics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 28515 Westinghouse Pl., Valencia, CA, 91355
Sources and methodology
- Original FDA record: P960058/S167
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






